



George B. Schoeler,*1 Cecilia Morón,† 
Allen Richards,‡ Patrick J. Blair,§ 
and James G. Olson§ 
Serum specimens from patients at 4 sites in Peru were
tested for evidence of spotted fever group rickettsial infec-
tion. Results showed that 30 (18%) of 170 patients had
spotted fever group rickettsial infections, which likely
caused their illnesses. These findings document laboratory-
confirmed spotted fever from diverse areas of Peru.
R
ickettsial spotted fever was first described in South
America in 1931 in Sao Paulo, Brazil (1). The etiolog-
ic agent, Rickettsia rickettsii, and the tick vector,
Amblyomma cajenennse (the Cayenne tick), were subse-
quently identified. Serologic evidence of R. rickettsii
infections has been documented in several countries in
South and central America, including Argentina (2), Brazil
and Uruguay (3), Colombia (4), Costa Rica (5), Panama
(6), and Mexico (7). A recent study documented for the
first time serologic evidence for spotted fever group (SFG)
Rickettsia infections in 1 region of northern Peru (8). We
describe serologic evidence of SFG rickettsial infections in
diverse areas of Peru, including laboratory-confirmed
infections among patients with clinical febrile disease. 
The Study
Serum samples were obtained from 4 areas in Peru:
Chiclayito and Salitral (Piura Department); La Merced
(Junin Department); and Cusco (Cusco Department)
(Figure). Chiclayito is a small village (population 6,133)
≈30 m above sea level on the outskirts of the city of Piura
in the northern coastal desert. Salitral is a small rural vil-
lage (population 1,503) ≈162 m above sea level in a more
temperate region of the Salitral District (Morropon
Province, Piura Department) ≈3 h by car from Chiclayito.
La Merced is the capital of the Chanchamayo District
(Chanchamayo Province, Junín Department) and located
≈751 m above sea level ≈350 km east of the Peruvian cap-
ital city of Lima, on the eastern side of the Andes. The dis-
trict has a population of 31,000; approximately half live in
La Merced. Cusco (population 260,000) is located ≈3,350
m above sea level in the southern Peruvian Andes 1,089
km southeast of Lima. 
Sera from patients representing the 4 surveillance sites
were tested for antibodies against SFG rickettsiae after
written informed consent was provided by each patient
(Department of Defense Institutional Review Board No.
31535). Patients enrolled had a fever ≥38ºC and at least 2
other signs or symptoms including headache, myalgia,
arthralgia, rash, and bleeding. Patients with a positive
blood film for malarial parasites or obvious disease such as
diarrhea or upper respiratory illness were excluded.
Paired (acute- and convalescent-phase) patient serum
samples were evaluated for immunoglobulin (Ig) G anti-
bodies reactive with R. rickettsii antigen by either an indi-
rect immunofluorescence assay (IFA) or enzyme
immunoassay (EIA). Serum specimens were also tested by
IFA for typhus group rickettsial antibodies and were uni-
formly negative. IFA analysis was conducted according to
directions provided by the manufacturer (PanBio, INDX,
Inc., Baltimore, MD, USA). Endpoint titers were recorded
as the reciprocal of the last dilution exhibiting specific flu-
orescence. Titers ≥1:64 were considered positive. Patients
with confirmed spotted fever were those who showed a ≥4-
fold increase in R. rickettsii IgG titer from acute phase to
convalescent phase of illness. 
The EIA was conducted by using a 4-step indirect
immunoassay to detect R. rickettsii IgG, as described (8).
A positive serum dilution exceeded the mean plus 3 stan-
dard deviations between the absorbance of R. rickettsii
antigen and the negative control antigen of 5 control serum
specimens. Serum samples were titrated to endpoint and
the highest dilution found positive was recoded as the R.
rickettsii IgG titer. Serum from a serologically confirmed
case-patient showed a ≥4-fold increase in antibody titer
from the acute to the convalescent phase.
A total of 170 patients, 50 from Chiclayito and the
Salitral Health Centers (Piura Department), 67 from Cusco
Hospital (Cusco Department), and 53 from La Merced
Hospital (Junin Department), were tested for antibodies to
SFG rickettsiae. IFA testing was done at the Peruvian
National Institute of Health, while EIAs were conducted at
Naval Medical Research Center Detachment. Not all
patients were tested by both assays (Table 1). Of the 170
patients tested, 30 (18%) yielded results that suggested that
SFG rickettsial infections were the most likely cause of
their illnesses (Table 1). Patients from all 4 study sites in 3
departments of Peru had evidence of SFG rickettsiae infec-
tions as the cause of illness. Frequencies of confirmed
patients in the 3 departments did not differ significantly
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Detachment, Lima, Peru(p > 0.52). Table 2 shows the frequencies of spotted fever
by age and sex for the 164 patients for whom data were
recorded. Age groups did not differ significantly (p > 0.5).
The frequency of spotted fever was 27% in female patients
and 10% in male patients (p < 0.005).
The signs and symptoms of patients with confirmed
spotted fever who came to the treatment facility included
fever and malaise (100%), chills (94%), weakness (94%),
shortness of breath (94%), prostration (81%), arthralgia
(62%), abdominal pain (62%), cough (56%), nausea
(56%), and runny nose (56%). None of the patients died,
and most patients had a relatively mild febrile illness.
There were no clear clinical differences in patients with
confirmed cases of spotted fever compared with febrile
patients who did not have spotted fever. 
Evidence of SFG rickettsial infection was observed in
samples taken from febrile patients in Cusco, Junin, and
Piura departments. The etiologic agent or agents responsi-
ble for the spotted fever illnesses remain unknown.
Appropriate samples from these patients were not avail-
able for isolation or molecular identification by a poly-
merase chain reaction.
Conclusions 
Host inflammation may partly contribute to the patho-
genic sequelae with intra-endothelial cell infection in more
severe SFG infection (9). Patients infected with R. akari
typically experience a mild and or asymptomatic disease
characterized by low-grade fever, sweats, headache, and a
vesicular eruption over the trunk and extremities (10). R.
akari is maintained transovarially in the mite vector and
transmitted to humans by the house mouse mite
(Liponyssoides sanguineus). Infections have generally
been reported among higher risk populations such as intra-
venous drug users (11), or within the densely populated
inner city (12). Less is known about the susceptibility of
rural agrarian populations. The concentration of humans in
close proximity to house mice and their mites are factors
that could contribute to an increase in rickettsialpox in the
region. Sporadic cases of rickettsialpox may be confused
with chickenpox, a common illness associated vesicular
rash. However, none of the confirmed SFG rickettsia-
infected patients had vesicular rashes typical of rick-
ettsialpox.  
Cat flea typhus, caused by R. felis, is a mild disease
similar to murine typhus (13). Typical clinical findings
include fever, headache, and occasional rash. The clinical
manifestations of patients infected with SFG rickettsiae
are similar to those described for cat flea typhus. However,
recent discoveries of novel rickettsioses caused by distinct
SFG rickettsiae in Europe, Africa, Australia, Asia, and
North America during the last 25 years (14,15) suggest that
the infections reported in this study may be the results of a
novel SFG rickettsial agent. Future work is needed to iden-
tify the agent involved and to clearly link clinical signs and
symptoms with diagnoses.
The higher frequency of cases in women suggests occu-
pational exposure since in these areas of Peru women are
generally more involved with domestic activities near the
home. Possibilities for increased exposure of women may
include more frequent work in the fields, thus exposing
them to arthropod vectors; closer contact with domestic
animals that may be involved in maintaining the SFG rick-
ettsial agent (although no evidence was collected to sup-
port this); or exposure to house mouse mites in the home.
Serologic evidence suggests that SFG rickettsiae were
responsible for causing febrile illnesses in these 4 study
sites of Peru, which demonstrates that SFG rickettsia result
in human disease in Peru. Further studies are needed to
document the species of SFG rickettsiae and to determine
the vectors of these rickettsial infections. In addition, epi-
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Figure. Four study sites in Peru surveyed for human spotted fever
rickettsial infections.demiologic studies are needed to identify the risk factors,
document the clinical spectrum, and suggest public health
recommendations for prevention.
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